Aronora raises funding round to support clot-buster drug development

The funding will enable Aronora to bring on more staff and to further the manufacturing of the company’s anti-coagulant drug candidates, CEO Erik Tucker said.

Previous Schizophrenia drug developer eyes late-stage clinical trial data this month
Next Hawaii senator asks President Biden for mortgage abatement for Lahaina residents